







an Open Access Journal by MDPI

## The Role of Thrombosis and Haemostasis in Cancer

Guest Editors:

### Prof. Dr. Marco Falasca

Department of Medicine and Surgery, University of Parma, Via Volturno, 39, 43125 Parma, Italy

### Dr. Pat Metharom

Platelet Research Laboratory, Curtin Health and Innovation Research Institute, Faculty of Health Sciences, Curtin University, Perth, WA 6102, Australia

Deadline for manuscript submissions:

closed (30 November 2018)

# **Message from the Guest Editors**

Dear Colleagues,

Cancer-associated thrombosis is a lethal complication in cancer sufferers. Cancer patients are at an estimated four to seven-fold increased risk of developing venous thromboembolism (VTE) compared to non-cancer individuals. The initiation of thrombotic event is attributed to the capability of cancer cells to activate the coagulation system, although the molecular mechanism is still poorly defined. Platelets, a key regulator cell population of haemostasis and thrombosis, are known to be an important contributor of VTE, not only to through their involvement in thrombus formation but also in promoting cancer survival and spread. Recently, neutrophils are implicated as an important mediator of cancer-associated thrombosis. Neutrophil extracellular traps (NETs), released from activated neutrophils, have been reported in tumour samples and their presence in vivo is associated with metastasis.

This Special Issue will cover the current research of thrombosis and haemostasis in cancer development.

Prof. Dr. Marco Falasca Dr. Pat Metharom Guest Editors













an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

# **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

### **Contact Us**